

## Daily evidence digest

16 August 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### COVID-19 mortality in Europe, AstraZeneca and Pfizer homologous and heterologous immunisation, surgical leadership during COVID-19

#### Peer reviewed journals featured:

- Observational studies on:
  - COVID-19 mortality trends in Europe [here](#)
  - Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with AstraZeneca and Pfizer [here](#)
  - SARS-CoV-2 antigen rapid immunoassay in the emergency department [here](#)
- A case study on leadership as an effective human factor during COVID-19 [here](#)

#### Letters and correspondence discussed:

- Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 wave [here](#)
- The need for GP awareness about post-acute COVID-19 conditions [here](#)
- Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients [here](#)

#### Pre-peer review articles featured:

- Neutralisation of variants of concern, one year following COVID-19 infection and 1-2 months following vaccination [here](#)
- Saliva molecular testing for monitoring and diagnosing SARS-CoV-2 infection in children [here](#)

#### Guidance and reports

- The Therapeutic Goods Administration (TGA) weekly COVID-19 vaccine safety report [here](#)

#### News and blogs

- How vaccinated people spread Delta [here](#)
- Schools are not hubs of infection and are safe to reopen after the summer break in England [here](#)
- Australia's COVID-19 experience [here](#)

[Click here](#) to subscribe to the daily evidence digest